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bjectives The aim of this study was to evaluate the effect of a concurrent chronic total occlusion
CTO) in patients with ST-segment elevation myocardial infarction (STEMI) on long-term mortality
nd left ventricular ejection fraction (LVEF).
ackground The impact of a CTO in a non–infarct-related artery (IRA) on prognosis after STEMI is
nknown.
ethods Between 1997 and 2005, we admitted 3,277 STEMI patients treated with primary percuta-
eous coronary intervention. Patients were categorized as single-vessel disease (SVD), multivessel
isease (MVD) without CTO, and MVD with a CTO in a non-IRA. We performed a “landmark survival
nalysis” to 5 years follow-up with a landmark set at 30 days. Additionally, we analyzed the evolu-
ion of LVEF within 1 year.
esults Of the patients, 2,115 (65%) had SVD, 742 patients (23%) had MVD without CTO, and 420
atients (13%) had a concurrent CTO. Presence of a CTO was a strong and independent predictor
or 30-day mortality (hazard ratio [HR]: 3.6, 95% conﬁdence interval [CI]: 2.6 to 4.7, p  0.01),
hereas MVD without CTO was a weak predictor (HR: 1.6, 95% CI: 1.2 to 2.2, p  0.01). In 30-day
urvivors, CTO remained a strong predictor (HR: 1.9, 95% CI: 1.4 to 2.8, p  0.01), and MVD lost its
ndependent prognostic value (HR: 1.1, 95% CI: 0.8 to 1.5, p  0.45). Furthermore, CTO was associ-
ted with LVEF 40% immediately after STEMI (odds ratio: 1.9, 95% CI: 1.3 to 2.8, p  0.01) and a
urther decrease in LVEF within the ﬁrst year (odds ratio: 3.5, 95% CI: 1.6 to 7.8, p  0.01).
onclusions The presence of a CTO and not MVD alone is associated with long-term mortality even
hen early deaths are excluded from analysis. The presence of a CTO is associated with reduced
VEF and further deterioration of LVEF. (J Am Coll Cardiol Intv 2009;2:1128–34) © 2009 by the
merican College of Cardiology Foundation
rom the Department of Cardiology, Academic Medical Center–University of Amsterdam, Amsterdam, the Netherlands.anuscript received July 27, 2009, accepted August 6, 2009.
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1129rimary percutaneous coronary intervention (PCI) in pa-
ients with ST-segment elevation myocardial infarction
STEMI) aims at early and sustained restoration of ante-
rade flow in the infarct-related artery (IRA). Successful
nd timely primary PCI leads to salvage of myocardium at
isk and reduces mortality (1). Angiography before primary
CI has shown that multivessel coronary artery disease
MVD) is present in 40% to 65% of patients with STEMI
nd is associated with higher morbidity and mortality after
eperfusion therapy (2–5). A concurrent chronic total oc-
lusion (CTO) in a non-IRA is present in 12% to 13% of
atients with STEMI (2,4). Recently we described in a
ohort of 1,417 STEMI patients that the effect of MVD on
ortality was primarily due to the presence of a CTO in a
on-IRA (4). However, in the relatively short-term follow
p period of 1 year, the majority of patients died within 30
ays. To provide further insight into the impact of a CTO
n a non-IRA on early and late mortality after STEMI we
erformed a “landmark survival analysis” with a landmark at
0 days, and we increased the total follow-up period to 5
ears. Furthermore, the size of our consecutive patient
ohort has more than doubled. In an attempt to further
nvestigate the effects of a CTO in a non-IRA after
TEMI, we additionally analyzed the impact of a CTO in
non-IRA on residual left ventricular ejection fraction
LVEF) immediately after primary PCI and during
ollow-up within the first year after primary PCI.
ethods
etween January 1997 and April 2006, a total of 3,562
onsecutive and unselected patients were admitted to our
ospital with STEMI. Acute STEMI was diagnosed when
atients had symptoms of an acute myocardial infarction
asting 30 min to 6 h, accompanied by an electrocardiogram
ith ST-segment elevation 1 mm (0.1 mV) in 2
ontiguous leads. Patients were immediately transported to
he catheterization laboratory and underwent immediate
ngiography with a view to perform primary PCI. If the
oronary anatomy was suitable for PCI, the procedure was
erformed with standard techniques. All procedural deci-
ions, including device selection and adjunctive pharmaco-
herapy, such as glycoprotein IIb/IIIa inhibitors, were made
t the discretion of the operator. All patients were treated
ith heparin and aspirin before PCI. If a coronary stent was
mplanted, ticlopidine or clopidogrel was prescribed accord-
ng to the guidelines.
Baseline clinical and angiographic data were collected
rospectively in a dedicated database. Upon the operator’s
nline assessment during emergency angiography, patients
ere categorized as having SVD, MVD without CTO, or
VD with concurrent CTO. For the purpose of this study,
VD was defined as 1 stenosis 70% of the coronaryumen diameter in 1 of the non–infarct-related epicardial erteries or left main stenosis 50%. A CTO was defined as
100% luminal narrowing in a non-IRA before PCI
ithout antegrade flow or with antegrade or retrograde
lling through collateral vessels. Per protocol, follow-up
ata including information on cardiac medication was col-
ected by written questionnaire sent to all patients after 1
ear. In addition, hospital records and outpatient reports
ere reviewed, and treating cardiologists were contacted.
inally, information on vital status was obtained from the
utch national population registry (Statistics Netherlands,
oorburg, the Netherlands) per April 2007. Data for the
,562 patients were checked for inconsistency and com-
leteness. Duplicate patients due to recurrent STEMI (n 
6), patients without confirmed diagnosis of STEMI (n 
32), and patients lost to follow-up (n 57) were excluded,
esulting in a final cohort of 3,277 patients with a median
ollow-up of 3.1 years (interquartile range [IQR]: 1.3 to
.6).
The LVEF was assessed by
ither global visual estimation
n echocardiography or by nu-
lear scintigraphy. Baseline
VEF was assessed within 1
onth after index event.
ollow-up LVEF was assessed
t least 1 month after but within
year of baseline LVEF mea-
urement. The LVEF compari-
on between baseline and
ollow-up was only performed if
erial measurements with the
ame technique were available.
tatistical analysis. Statistical
nalysis was performed with
PSS statistical software version
5.0 (SPSS, Inc., Chicago, Illi-
ois). Differences in baseline
haracteristics between the 3 groups were tested for signif-
cance by the chi-square test. Statistical significance was
efined as a p  0.05.
Cumulative event rates for death were calculated accord-
ng to the Kaplan-Meier method. Survival curves were
onstructed with Kaplan-Meier estimates and compared by
og-rank tests. Follow-up for mortality was censored at the
ate of last follow-up by checking vital status in the Dutch
opulation registry or at 5 years, whichever came first. We
erformed a “landmark survival analysis” with a landmark
et at 30 days to provide insight into the differences in early
nd late death rates in patients with SVD, MVD without
TO, and MVD with concurrent CTO.
Hazard ratios (HRs) for death were calculated with Cox
roportional hazard regression analyses after verification of
he proportional hazards assumption. To correct for differ-
Abbreviations
and Acronyms
CI  confidence interval
CTO  chronic total
occlusion
HR  hazard ratio
IQR  interquartile range
IRA  infarct-related artery
LVEF  left ventricular
ejection fraction
MVD  multivessel disease
OR  odds ratio
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
SVD  single-vessel diseasences in baseline variables and residual LVEF, we per-
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1130ormed forward stepwise Cox regression multivariate anal-
sis, including all clinical and angiographic variables with a
ignificantly different distribution in the model. Covariates
ncluded in multivariate analysis include MVD without
oncurrent CTO, age 60 years, male sex, hypertension,
moking, diabetes mellitus, hypercholesterolemia, previous
I, shock, left anterior descending coronary artery-related
I, procedural success, and post-PCI TIMI flow grade 3.
covariate was allowed in the model if it influenced the
odel with a likelihood ratio significance level of p  0.05
nd removed if its significance level exceeded p  0.1.
The LVEF was dichotomized as either 40% or 40%.
his cutoff point for left ventricular function was prese-
ected, because of its well-recognized clinical significance
6). To study the effect of a concurrent CTO on recovery of
eft ventricular function, LVEF was stratified into 4 incre-
ental categories: 50%, 41% to 50%, 30% to 40%, and
30%. Recovery of LVEF was defined as an increase in
VEF by at least 1 category, unchanged LVEF was defined
s no change in category, and decreased LVEF was defined
s a decrease by at least 1 category.
To study the independent value of a concurrent CTO on
esidual LVEF after primary PCI for STEMI and on
ecreased LVEF at follow-up, stepwise logistic regression
as used, including the aforementioned variables in the
nalyses. Patients who were already in the lowest category
Table 1. Baseline Clinical and Angiographic Characteristics
Total STEMI Cohort
(n  3,277)
p Value
SVD
(n  2,115)
(65%)
MVD
(n  742)
(23%)
CTO
(n  420)
(13%)
(n 
(
Baseline characteristics
Age 60 yrs 928 (44) 464 (63) 276 (66) 0.01 5
Male 1,498 (71) 554 (75) 315 (75) 0.04 8
Hypertension 598 (28) 266 (36) 136 (32) 0.01 3
Smoker 1,045 (49) 283 (38) 159 (38) 0.01 5
Diabetes 183 (8.7) 118 (16) 82 (20) 0.01
Hypercholesterolemia 443 (21) 175 (24) 120 (29) 0.01 2
Family history of CVD 873 (41) 306 (41) 151 (36) 0.12 4
Previous MI 190 (9.0) 141 (19) 163 (39) 0.01
Shock 145 (6.9) 87 (12) 91 (22) 0.01
Angiographic characteristics
LAD-related MI 1,045 (49) 295 (40) 210 (50) 0.01 6
RCX-related MI 268 (13) 102 (14) 82 (20) 0.01 1
RCA-related MI 799 (38) 344 (46) 127 (30) 0.01 4
Procedural success 2,003 (97) 686 (95) 360 (91) 0.01 1,1
Pre-PCI TIMI ﬂow grade 0 1,394 (66) 481 (65) 271 (65) 0.34 7
Post-PCI TIMI ﬂow grade 3 1,866 (88) 620 (84) 337 (80) 0.01 1,0
Categorical variables are described as absolute numbers (%) and compared by means of the chi-sq
CTO  chronic total occlusion; CVD  cardiovascular disease; LAD  left anterior descending c
PCI percutaneous coronary intervention; RCA right coronary artery; RCX circumflex coronaror LVEF (n  15) were excluded from this last analysis. mesults
ollow-up was complete for all patients with a follow-up
uration of at least 1 year. Median follow-up duration was
.1 years (IQR 1.3 to 4.6). Among the 3,277 patients with
TEMI, 2,115 patients (65%) had SVD, 742 patients (23%)
ad MVD without CTO, and 420 patients (13%) had
VD with a concurrent CTO. Table 1 shows the baseline
linical and angiographic characteristics for the 3 patient
roups. Patients with MVD (with or without concurrent
TO) were older and more often had hypertension, hyper-
holesterolemia, and diabetes compared with SVD patients.
urthermore, CTO patients more often had a previous MI
nd cardiogenic shock at presentation compared with pa-
ients with SVD and MVD without CTO.
ortality. Figure 1 shows the cumulative mortality for
atients with SVD, MVD without CTO, and MVD with a
oncurrent CTO during the first 30 days after STEMI and
he 5 years thereafter. Kaplan-Meier estimates for death at
0 days were 4.9% in the SVD group, 9.7% in the MVD
ithout CTO group, and 24% in the MVD with concurrent
TO group. Kaplan-Meier estimates for death at 5 years,
xcluding patients who died within the first 30 days after
TEMI were 10% in the SVD group, 12% in the MVD
ithout CTO group, and 19% in the MVD with concurrent
TO group. Finally, Kaplan-Meier estimates for total
ts With LVEF Available
(n  1,745)
p Value
Patients With Serial LVEF
(n  356)
p Value
9)
MVD
(n  386)
(22%)
CTO
(n  200)
(11%)
SVD
(n  247)
(69%)
MVD
(n  75)
(21%)
CTO
(n  34)
(10%)
) 226 (59) 132 (66) 0.01 95 (39) 42 (56) 20 (59) 0.01
) 293 (76) 153 (77) 0.25 185 (75) 60 (80) 28 (83) 0.47
) 143 (37) 74 (37) 0.01 72 (29) 31 (41) 15 (44) 0.05
) 150 (39) 79 (40) 0.01 123 (50) 36 (48) 17 (50) 0.96
) 62 (16) 41 (21) 0.01 17 (6.9) 16 (21) 8 (23) 0.01
) 94 (24) 60 (30) 0.01 52 (21) 18 (24) 15 (44) 0.01
) 169 (44) 79 (40) 0.61 111 (45) 37 (49) 15 (45) 0.78
) 61 (16) 71 (36) 0.01 18 (7.3) 15 (20) 9 (27) 0.01
) 40 (10) 34 (17) 0.01 22 (8.9) 9 (12) 6 (18) 0.26
) 157 (41) 89 (45) 0.01 152 (62) 36 (48) 19 (56) 0.11
) 52 (14) 38 (19) 0.04 56 (11) 10 (13) 3 (8.8) 0.73
) 176 (46) 73 (37) 0.01 69 (28) 29 (39) 12 (35) 0.18
) 366 (97) 180 (94) 0.12 235 (97) 70 (93) 32 (94) 0.08
) 245 (64) 129 (65) 0.24 167 (68) 49 (65) 21 (62) 0.85
) 333 (87) 166 (83) 0.06 220 (89) 63 (84) 30 (88) 0.50
t.
y artery; LM  left main coronary artery; MI  myocardial infarction; MVD  multivessel disease;
; SVD single-vessel disease; TIMI Thrombolysis In Myocardial Infarction.Patien
SVD
1,15
66%)
03 (43
39 (72
35 (29
92 (51
98 (8.5
37 (20
94 (43
91 (7.9
82 (7.1
06 (52
43 (12
09 (35
01 (98
56 (65
27 (89
uare tes
oronarortality at 5 years were 14% in the SVD group, 20% in the
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1131VD without CTO group, and 38% in the MVD with
oncurrent CTO group.
During the first 30 days after STEMI, the mortality rate
as significantly higher in patients with a concurrent CTO
n a non-IRA, compared with patients with SVD (unad-
usted HR: 5.3, 95% confidence interval [CI]: 4.0 to 7.0,
 0.01). Compared with patients with SVD, mortality
as also higher in patients with MVD without a concurrent
TO (unadjusted HR: 2.0, 95% CI: 1.5 to 2.7, p  0.01).
able 2 shows the adjusted Cox proportional HRs for death
uring the first 30 days, and during 30 days to 5 years after
rimary PCI. After adjusting for the aforementioned vari-
bles, the presence of a CTO in a non-IRA was still found
o be a strong and independent predictor for both 30-day
ortality, with an HR of 3.6 (95% CI: 2.6 to 4.7, p 0.01)
Figure 1. Landmark Survival Analysis
Cumulative risk of death during the ﬁrst 30 days after primary percutane-
ous coronary intervention (PCI) and thereafter for patients with single-
vessel disease (SVD), multivessel disease (MVD), and a chronic total occlu-
sion (CTO).
Table 2. Independent Predictors for Death During the First 30 Days and Du
Predictors for Death During the Fi
After Primary PCI
HR 95% CI
Shock 7.4 5.8–9.6
CTO 3.6 2.6–4.7
MVD without CTO 1.6 1.2–2.2
LAD-related MI 1.4 1.1–1.7
Hypertension 0.7 0.5–0.9
Hypercholesterolemia 0.6 0.5–0.9
Smoking 0.5 0.4–0.7
Post-PCI TIMI ﬂow grade 3 0.4 0.3–0.5
Age 60 yrs 1.3 0.9–1.7
Covariates were allowed in the forward stepwise Cox regressionmodel if they influenced themodel
Covariates that were included in the analysis but were removed: male sex, diabetes mellitus, and p
without CTO,” “Hypertension,” “Hypercholesterolemia,” and “Smoking” were forced into the modelCI confidence interval; HR hazard ratio; other abbreviations as in Table 1.nd 5-year mortality, excluding deaths within the first 30
ays (HR: 1.9, 95% CI: 0.8 to 1.6, p  0.01). The presence
f MVD without a concurrent CTO was also found to be a
tatistically significant independent predictor for 30-day
ortality (HR: 1.6, 95% CI: 1.2 to 2.2, p  0.01) but not
or 5-year mortality excluding deaths within the first 30 days
HR: 1.1, 95% CI: 0.8 to 1.6, p  0.51).
mpact of a CTO on LVEF. In our study population of 3,277
atients, residual LVEF measurements were available in
,745 patients (53%). A total of 1,674 patients underwent
chocardiography, and 71 patients underwent scintigraphy
ithin 30 days after the index event. Median time to LVEF
easurement was 3 days (IQR 2 to 5 days); time to LVEF
easurement was not statistically different among SVD,
VD, and CTO patient groups. Among the 1,745 patients
or whom LVEF data were retrieved, 1,159 patients (66%)
ad SVD, 386 patients (22%) had MVD, and 200 patients
11%) had a concurrent CTO. The baseline clinical and
ngiographic characteristics of patients with LVEF are
hown in Table 1 and compare well to characteristics of the
otal cohort. This indicates that this subset seems a repre-
entative sample of the total STEMI cohort.
Of the 1,745 patients, a total of 307 patients (18%) had
n LVEF40%. Figure 2 shows the proportions of patients
ith an LVEF 40% in each patient group. The propor-
ions of patients with an LVEF 40% were 16% in the
VD group, 18% in the MVD without CTO group, and
8% in the MVD with concurrent CTO group (p  0.01).
he presence of a CTO in a non–IRA was a significant
redictor for a residual LVEF 40% (odds ratio [OR]: 2.0,
5% CI: 1.4 to 2.8). After correction for the presence of
VD without CTO and differences in the aforementioned
ariables, the presence of a CTO in a non-IRA remained an
ndependent predictor for a residual LVEF 40% with an
R of 1.8 (95% CI: 1.2 to 2.7, p  0.01). Other indepen-
0 Days to 5 Years After Primary PCI
Days Predictors for Death From 30 Days to 5 Yrs
After Primary PCI
p Value HR 95% CI p Value
0.01 1.6 1.0–2.4 0.04
0.01 1.9 1.4–2.8 0.01
0.01 1.1 0.8–1.6 0.51
0.01 1.7 1.3–2.2 0.01
0.01 1.1 0.8–1/5 0.52
0.01 0.8 0.6–1.1 0.12
0.01 0.8 0.6–1.0 0.07
0.01 0.6 0.5–0.9 0.01
0.13 3.3 2.4–4.5 0.01
ikelihood ratio significance level of p 0.05 and removed if its significance level exceeded p 0.1.
MI. The variable “Age60 yrs” was forced into the model for the first 30 days. The variables “MVD
5 yrs thereafter.ring 3
rst 30
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1132ent predictors for a residual LVEF 40% are shown in
able 3.
eft ventricular function during follow-up. Of the 1,745
atients with baseline LVEF available, serial LVEF mea-
urements were performed in 356 patients (20%). A total of
42 patients (68%) were classified as having SVD, 74 (21%)
s having MVD without CTO, and 36 (10%) as having
VD with a concurrent CTO. Baseline clinical and pro-
edural characteristics are shown in Table 1.
Echocardiography was the only imaging modality used in
his subgroup of patients with serial LVEF measurements.
edian time between baseline and follow-up echo was 177
ays (IQR 89 to 285) with no significant differences in time
etween echoes among the 3 groups. Patients with SVD
ore often showed an increase in LVEF at follow-up
ompared with patients with MVD with and without
oncurrent CTO (p  0.02). The proportion of patients
Figure 2. Proportion of Patients With LVEF <40% After ST-Segment
Elevation Myocardial Infarction
LVEF  left ventricular ejection fraction; Pts  patients; other abbreviations
as in Figure 1.
Table 3. Independent Predictors for LVEF <40% After STEMI
OR 95% CI p Value
LAD-related MI 5.3 3.9–7.2 0.01
Shock 2.6 1.7–3.8 0.01
Diabetes mellitus 1.7 1.1–2.5 0.01
CTO 1.9 1.3–2.8 0.01
Age 60 yrs 1.5 1.1–2.3 0.01
Previous MI 1.6 1.1–2.3 0.02
Hypertension 0.6 0.5–0.9 0.01
MVD without CTO 1.2 0.9–1.7 0.27
Covariates were allowed in the logistic regression model if they influenced the model with a
likelihood ratio significance level of p 0.05 and removed if its significance level exceeded p
0.1. Covariates that were included in the analysis but were removed: male sex, smoking, hyper-
cholesterolemia, and procedural success. MVD without CTO was forced into the model.
LVEF  left ventricular ejection fraction; OR  odds ratio; STEMI  ST-segment elevationmyocardial infarction; other abbreviations as in Tables 1 and 2.ho had an increase in LVEF was 37%, 24%, and 21% for
atients with SVD, MVD without CTO, and MVD with
oncurrent CTO, respectively. Figure 3 shows the propor-
ions of patients who had a decrease in LVEF at follow-up
n each patient group. Patients with a concurrent CTO
ignificantly more often had a decrease in LVEF compared
ith patients with SVD and MVD without CTO (p 
.01). The proportion of patients who had a decrease in
VEF was 14%, 19%, and 39% for patients with SVD,
VD without CTO, and MVD with concurrent CTO,
espectively.
Logistic regression analysis was used to identify indepen-
ent predictors of deterioration of LVEF. After correction
or the aforementioned variables, the presence of a concur-
ent CTO was associated with a decrease in LVEF with an
R of 3.5 (95% CI: 1.6. to 7.8, p  0.01). Patients older
han 60 years were found to have an OR of 1.9 (95% CI: 1.0
o 3.4, p  0.03) for a decrease in LVEF (Table 4). The
resence of MVD without CTO was not independently
ssociated with a decrease in LVEF (OR: 1.3, 95% CI: 0.6
o 2.6, p  0.26).
Figure 3. Proportion of Patients With a Decrease in LVEF of at Least
1 Category Between Baseline and 1-Year Follow-Up
FUP  follow-up; other abbreviations as in Figures 1 and 2.
Table 4. Independent Predictors for a Decrease in LVEF During Follow-Up
OR 95% CI p Value
Age 60 yrs 1.9 1.0–3.4 0.03
CTO 3.5 1.6–7.8 0.01
MVD without CTO 1.3 0.6–2.6 0.64
Covariates were allowed in the logistic regression model if they influenced the model with a
likelihood ratio significance level of p 0.05 and removed if its significance level exceeded p
0.1.Covariates that were included in the analysis but were removed: male sex, shock, diabetes,
LAD-related infarction, hypertension, hypercholesterolemia, smoking, previous MI, and proce-
dural success. MVD without CTO was forced into the model.Abbreviations as in Tables 1 and 3.
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1133iscussion
ur study in a cohort of 3,277 patients confirmed and
xtended the previous observation that the impact of MVD
n mortality in STEMI patients is almost entirely due to the
resence of a CTO and not due to the presence of MVD
lone (2). The presence of a CTO in a non-IRA was found
o be a strong and independent predictor for both early
ortality (within 30 days after STEMI) and late mortality
from 30 days to 5 years after STEMI). In contrast, MVD
ithout a concurrent CTO was found to be only a relatively
eak predictor for early mortality. Moreover, MVD without
TO lost its independent predictive value for mortality
fter excluding patients who died within 30 days after
TEMI. Furthermore, we found that a CTO and not
VD alone is associated with both a reduced residual
VEF after the index event and a further deterioration in
VEF during follow-up.
The high mortality rate of STEMI patients with a
oncurrent CTO can in part be explained by the higher risk
rofile of CTO patients. The CTO patients had more risk
actors associated with worse clinical outcome when com-
ared with SVD patients. Additionally, they more often had
previous MI and presented more often in shock on
dmission when compared with SVD patients and MVD
atients without CTO. However, after adjustment for these
ifferences in baseline characteristics, the presence of a
TO in a non-IRA remained a strong and independent
redictor for early mortality with an HR of 3.6 and for late
ortality with an HR of 1.9. The presence of MVD
ithout a CTO was also a statistically significant predictor
or early mortality although substantially less powerful with
n HR of only 1.6. Only cardiogenic shock was a more
otent predictor for early mortality, with an HR of 7.4. Age
60 years was the only more potent predictor for late
ortality, with an HR of 3.3.
In an attempt to further explore the underlying mecha-
ism for the increased mortality in STEMI patients with a
oncurrent CTO, we analyzed residual LVEF in 1,745
atients. The baseline characteristics of these 1,745 patients
ompare well to those of the entire STEMI cohort, indi-
ating that they were a representative sample. As expected,
he proportion of patients with a residual LVEF 40% was
ignificantly higher in CTO patients (28%) compared with
VD patients (16%) and MVD patients without CTO
18%). The difference between the 2 latter groups was
onsignificant. Even after correction for differences in
aseline characteristics in a multivariate logistic regression
odel, the presence of a CTO remained a strong predictor
or a residual LVEF 40%. The presence of MVD alone
as not associated with an LVEF 40%.
By analyzing serial echocardiograms, we found that
atients with a CTO in a non-IRA more often had a further
ecrease of LVEF in the first year after the index STEMI. cn a multivariate model, the presence of a CTO was
ssociated with a decrease in LVEF with an OR of 3.5,
hereas the presence of MVD alone was not associated with
decrease in LVEF. These findings suggest that STEMI
atients with a CTO in a non-IRA undergo a more
ronounced negative left ventricular remodeling process.
his can also, at least partly, explain the higher mortality
mong patients with a CTO in a non-IRA.
linical implications. Currently, multivessel PCI during pri-
ary PCI in the absence of cardiogenic shock or multiple
ulprit arteries is discouraged, because a beneficial effect on
linical end points has not been demonstrated (7). The only
small-sized randomized trials investigating multivessel
CI during the index event failed to show a clinical benefit
rom multivessel PCI (8,9). Although, in these 2 trials,
ultivessel PCI was not associated with an increased rate of
n-hospital complications, it is likely that multivessel PCI is
ssociated with an increased risk of contrast nephropathy.
dditionally, multivessel PCI in the prothrombotic milieu
f the hyperacute phase of infarction might result in more
dverse thrombotic events (10–12). A number of observa-
ional studies are hampered by selection bias and have
eported inconclusive results (13–17).
The current study might at least partly explain why a
enefit for multivessel PCI has not been clearly demon-
trated. In our cohort, we found that the presence of a CTO
n a non-IRA drives mortality in MVD patients. Only 30%
f MVD patients have a concurrent CTO; moreover, CTO
atients have been excluded from previous studies because
f the high complexity of these lesions. The current study
dentified a CTO in a non-IRA as a potentially modifiable
isk factor for both short- and long-term mortality after
TEMI. An adequately powered randomized controlled
rial is warranted to investigate a possible benefit of opening
CTO early after STEMI. Therefore we have recently
nitiated the randomized controlled international multi-
enter EXPLORE (Evaluating XIENCE V and LVF in
CI on Occlusions after STEMI) trial (18). This trial will
nvestigate the effects of opening a concurrent CTO on LV
unction and remodeling after PCI for STEMI.
tudy limitations. There are several limitations to this study,
he main limitation being its observational nature. Non-
ulprit lesion stenosis severity was assessed at the infarct
ngiography in the acute setting and by the performing
ardiologist. Therefore, some overestimation of non-culprit
esions might have occurred (19). This might, for a small
art, account for the good prognosis of MVD patients
ithout CTO in this study. Detailed information on peri-
nd post-procedural medication was not available; therefore
e were not able to assess differences in adherence to
uideline-based post-STEMI therapies. Unfortunately,
VEF assessment was not routinely performed in all pa-
ients. Additionally, LVEF was measured with incremental
ategories and not as a continuous variable. Although
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1134VEF assessment was not available in all patients, the
aseline characteristics compare well between the LVEF
ubsets of patients and the total STEMI cohort, indicating
hat these subsets are a representative sample of the total
TEMI cohort. Furthermore, the unfavorable effects of a
TO in a non-IRA were found consistently in every
nalysis.
onclusions
he poor prognosis of STEMI patients with MVD is
riven by the presence of a CTO in a non-IRA. The
resence of a CTO and not MVD alone is associated with
ong-term mortality, even when early deaths are excluded
rom analysis. Furthermore, the presence of a CTO and not
VD alone is associated with reduced residual LVEF after
he index event and with a further deterioration of LVEF
uring follow-up. These findings warrant further investiga-
ion on additional revascularization of CTOs in STEMI
atients with MVD.
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